Press coverage about AbbVie (NYSE:ABBV) has been trending somewhat positive on Friday, according to AlphaOne. AlphaOne, a subsidiary of Accern, rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AbbVie earned a news sentiment score of 0.12 on AlphaOne’s scale. AlphaOne also assigned media headlines about the company an impact score of 81 out of 100, meaning that recent news coverage is very likely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted Alpha One Sentiment Analysis’s analysis:
- AbbVie’s (ABBV) Cancer Candidate Fails in Phase III Studies – Yahoo Finance (finance.yahoo.com)
- Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C (finance.yahoo.com)
- AbbVie’s veliparib flop no big deal – analysts – Seeking Alpha (seekingalpha.com)
- AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies (finance.yahoo.com)
- AbbVie's PARP Inhibitor Comes Up Empty (finance.yahoo.com)
Shares of AbbVie (NYSE:ABBV) opened at 63.78 on Friday. The company has a market cap of $101.66 billion, a P/E ratio of 17.57 and a beta of 1.57. AbbVie has a 12 month low of $55.06 and a 12 month high of $68.12. The stock’s 50 day moving average is $64.94 and its 200 day moving average is $62.19.
AbbVie (NYSE:ABBV) last posted its earnings results on Friday, January 27th. The company reported $1.20 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.20. AbbVie had a net margin of 23.22% and a return on equity of 141.55%. The firm earned $6.78 billion during the quarter, compared to analyst estimates of $6.92 billion. During the same quarter in the prior year, the business posted $1.13 EPS. The business’s revenue was up 6.0% compared to the same quarter last year. On average, analysts anticipate that AbbVie will post $5.50 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, May 15th. Stockholders of record on Thursday, April 13th will be paid a $0.64 dividend. The ex-dividend date is Tuesday, April 11th. This represents a $2.56 annualized dividend and a dividend yield of 4.01%. AbbVie’s payout ratio is 70.52%.
ABBV has been the topic of several analyst reports. Vetr lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating and set a $67.88 price objective on the stock. in a report on Tuesday, January 31st. Societe Generale raised shares of AbbVie from a “sell” rating to a “hold” rating in a research note on Wednesday, March 22nd. Goldman Sachs Group Inc raised shares of AbbVie from a “buy” rating to a “conviction-buy” rating and upped their target price for the company from $74.00 to $80.00 in a research note on Saturday, March 11th. BMO Capital Markets reaffirmed a “hold” rating and issued a $63.00 target price on shares of AbbVie in a research note on Wednesday, March 22nd. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of AbbVie in a research note on Tuesday, February 14th. Ten investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. AbbVie has a consensus rating of “Buy” and an average target price of $72.17.
In other news, Chairman Richard A. Gonzalez sold 72,016 shares of the company’s stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $64.25, for a total value of $4,627,028.00. Following the completion of the sale, the chairman now owns 369,113 shares in the company, valued at approximately $23,715,510.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Laura J. Schumacher sold 40,000 shares of the company’s stock in a transaction on Friday, March 10th. The stock was sold at an average price of $65.26, for a total transaction of $2,610,400.00. Following the completion of the sale, the insider now owns 147,415 shares of the company’s stock, valued at approximately $9,620,302.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 139,599 shares of company stock valued at $9,038,322. Company insiders own 0.11% of the company’s stock.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2066244/somewhat-favorable-press-coverage-very-likely-to-affect-abbvie-abbv-stock-price.html
Receive News & Ratings for AbbVie Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc and related companies with MarketBeat.com's FREE daily email newsletter.